The state of New York currently has 5 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Recruiting
This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting. PBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many participants with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. In this stu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Northwell Health Inc, Center for Liver Disease and Transplantation, Manhasset, New York
Conditions: Primary Biliary Cholangitis
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: NYU Langone Gastroenterology and Hepatology Associates, New York, New York
Conditions: Primary Biliary Cholangitis (PBC)
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York +2 locations
Conditions: Primary Biliary Cholangitis
Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis
Recruiting
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Zydus US035, Rochester, New York
Conditions: Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Recruiting
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: New York University Hepatology Associates, New York, New York
Conditions: Primary Biliary Cholangitis